“In cell therapy, we expect to provide a pivotal update from the Phase II iMMagine-1 trial evaluating anito-cel for multiple myeloma later this year.”

In context

“, we plan to share updates from ARTISTRY-1 and ARTISTRY-2. These Phase III trials are evaluating a potential new single-tablet regimen combining bictegravir plus lenacapavir that could further extend the reach of Gilead's current HIV treatment business. Moving to oncology. We announced back-to-back positive Phase III results for Trodelvy with the top line data from ASCENT-03 and the detailed data from ASCENT-04. We now have data that show highly statistically significant and clinically meaningful benefit for Trodelvy across first-line metastatic triple-negative breast cancer. Trodelvy is already the leading therapy for second-line metastatic TNBC. And with these data, we look forward to potentially advancing Trodelvy to the first-line setting where it could benefit twice as many patients. In cell therapy, we expect to provide a pivotal update from the Phase II iMMagine-1 trial evaluating anito-cel for multiple myeloma later this year. Given the compelling efficacy and safety data seen to date, combined with Kite's industry-leading manufacturing capabilities, we believe “anito-cel is well positioned as a potential best-in-class therapy for multiple myeloma. In summary, this is a very special time for Gilead that's underscored with our second quarter results. This highlights the strength of our R&D engine and the level of excellence in our commercial and operational execution. Having built this positive momentum, we're excited by what's to come with continued innovation that will benefit patients and drive growth across our therapeutic areas. With that, I'll hand over to Johanna. Johanna Mercier: Thanks, Dan, and good afternoon, everyone. We had another very strong quarter of commercial execution, culminating with the la”